References
Cheng D, Noble J, Tang MX, Schupf N, Mayeux R, Luchsinger JA. Type 2 diabetes and late-onset Alzheimer’s disease. Dement Geriatr Cogn Disord 2011, 31: 424–430.
Craft S, Baker LD, Montine TJ, Minoshima S, Watson GS, Claxton A, et al. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol 2012, 69: 29–38.
Shankar A, Teppala S. Relationship between body mass index and high cystatin levels among US adults. J Clin Hypertens (Greenwich) 2011, 13: 925–930.
Uruska A, Araszkiewicz A, Zozulinska-Ziolkiewicz D, Wegner M, Grzelka A, Wierusz-Wysocka B. Does serum cystatin C level reflect insulin resistance in patients with type 1 diabetes? Clin Biochem 2014, 47: 1235–1238.
Ji X, Yao L, Wang M, Liu X, Peng S, Li K, et al. Cystatin C attenuates insulin signaling transduction by promoting endoplasmic reticulum stress in hepatocytes. FEBS Lett 2015, 589: 3938–3944.
Emanuelli B, Peraldi P, Filloux C, Chavey C, Freidinger K, Hilton DJ, et al. SOCS-3 inhibits insulin signaling and is up-regulated in response to tumor necrosis factor-alpha in the adipose tissue of obese mice. J Biol Chem 2001, 276: 47944–47949.
Yasuhara O, Hanai K, Ohkubo I, Sasaki M, McGeer PL, Kimura H. Expression of cystatin C in rat, monkey and human brains. Brain Res 1993, 628: 85–92.
Hakansson K, Huh C, Grubb A, Karlsson S, Abrahamson M. Mouse and rat cystatin C: Escherichia coli production, characterization and tissue distribution. Comp Biochem Physiol B Biochem Mol Biol 1996, 114: 303–311.
Grubb A. Diagnostic value of analysis of cystatin C and protein HC in biological fluids. Clin Nephrol 1992, 38 Suppl 1: S20–27.
Shlipak MG, Sarnak MJ, Katz R, Fried LF, Seliger SL, Newman AB, et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med 2005, 352: 2049–2060.
Gauthier S, Kaur G, Mi W, Tizon B, Levy E. Protective mechanisms by cystatin C in neurodegenerative diseases. Front Biosci (Schol Ed) 2011, 3: 541–554.
Ueki K, Kondo T, Kahn CR. Suppressor of cytokine signaling 1 (SOCS-1) and SOCS-3 cause insulin resistance through inhibition of tyrosine phosphorylation of insulin receptor substrate proteins by discrete mechanisms. Mol Cell Biol 2004, 24: 5434–5446.
Sarnak MJ, Katz R, Fried LF, Siscovick D, Kestenbaum B, Seliger S, et al. Cystatin C and aging success. Arch Intern Med 2008, 168: 147–153.
Acknowledgements
This work was supported by the National Natural Science Foundation of China (81471037 and 81770841); the “Six Kinds of Talents Summit” of Jiangsu Province, China (SWYY-051); Basic Research Program of Education Department of Jiangsu Province, China (14KJA180006); the Program for New Technology of Clinical Diagnosis and Treatment at Nantong (MS22016024); Priority Academic Development Program of Jiangsu Higher Education Institutions.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
All authors claim that there are no conflicts of interest.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Luo, L., Ma, J., Li, Y. et al. Cystatin C Induces Insulin Resistance in Hippocampal Neurons and Promotes Cognitive Dysfunction in Rodents. Neurosci. Bull. 34, 543–545 (2018). https://doi.org/10.1007/s12264-018-0226-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12264-018-0226-6